Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.51 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.51 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.51 |
| ▸ | ECE1 | P42892 | 2/20 | 0.50 |
| ▸ | GRM8 | O00222 | 1/20 | 0.50 |
| ▸ | GRM6 | O15303 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.50 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3919265 | 1.00 | DPP4 (0.51) | DPP4DPP8DPP9ECE1GRM8 | |
| SCHEMBL29517221 | 1.00 | DPP4 (0.51) | DPP4DPP8DPP9ECE1GRM8 | |
| Hydrochloric Acid SCHEMBL10636183 | 0.98 | DPP4 (0.50) | DPP4DPP8DPP9ECE1GRM8 | |
| SCHEMBL31339431 | 0.98 | BACE1 (0.51) | DPP4DPP8DPP9ECE1GRM8 | |
| SCHEMBL29517591 | 0.95 | BACE1 (0.50) | DPP4DPP8DPP9ECE1GRM8 | |
| SCHEMBL31314398 | 0.95 | BACE1 (0.49) | DPP4DPP8DPP9ECE1GRM8 | |
| SCHEMBL30423552 | 0.95 | BACE1 (0.49) | DPP4DPP8DPP9ECE1GRM8 | |
| SCHEMBL29575299 | 0.95 | BACE1 (0.50) | DPP4DPP8DPP9ECE1GRM8 | |
| SCHEMBL30596289 | 0.93 | BACE1 (0.48) | DPP4DPP8DPP9ECE1GRM8 | |
| SCHEMBL30553776 | 0.92 | BACE1 (0.50) | DPP4DPP8DPP9ECE1GRM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-26 | — | — | US | claimed |
| EP-4583917-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2025-07-16 | — | — | EP | claimed |
| CN-119923279-A | Prostate Specific Membrane Antigen (PSMA) ligands and uses thereof | 3B制药有限公司 | 2025-05-02 | — | — | CN | claimed |
| CN-119751572-A | Elm Huang Gutai, and preparation and application thereof | 昆明理工大学 | 2025-04-04 | — | — | CN | claimed |
| WO-2024052431-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2024-03-14 | — | — | WO | claimed |
| CN-117567564-A | Polypeptide derivative and preparation method and application thereof | 山东省农业科学院 | 2024-02-20 | — | — | CN | claimed |
| CN-116496353-A | Polypeptide derivative and preparation method and application thereof | 山东省农业科学院 | 2023-07-28 | — | — | CN | claimed |
| CN-115340996-A | Co-expression method of multi-subunit protein by using specific enzyme cutting site | 态创生物科技(广州)有限公司 | 2022-11-15 | — | — | CN | claimed |
| US-20220175871-A1 | PEPTIDE HAVING ANTIOXIDANT ACTIVITY AND COMPOSITION CONTAINING SAME | SEMPIO FOODS COMPANY (KR) | 2022-06-09 | — | — | US | claimed |
| CN-119751572-B | Elm Huang Gutai, and preparation and application thereof | 昆明理工大学 | 2026-05-05 | — | — | CN | disclosed |
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-26 | — | — | US | disclosed |
| CN-121652228-A | Elm Huang Gutai, and preparation and application thereof | 昆明理工大学 | 2026-03-13 | — | — | CN | disclosed |
| EP-4583917-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2025-07-16 | — | — | EP | disclosed |
| CN-119923279-A | Prostate Specific Membrane Antigen (PSMA) ligands and uses thereof | 3B制药有限公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-116348481-A | Materials and methods using engineered ligands | 詹森生物科技公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-114246342-B | High-chelating-activity small-molecule peptide chelated ferrous iron, preparation method and application of iron supplement | 安徽农业大学 | 2022-12-13 | — | — | CN | disclosed |
| CN-114246342-B | High-chelating-activity small-molecule peptide chelated ferrous iron, preparation method and application of iron supplement | 安徽农业大学 | 2022-12-13 | — | — | CN | disclosed |
| US-11524979-B2 | Macrocyclic polypeptides | UNIVERSITY OF WASHINGTON (US) | 2022-12-13 | — | — | US | disclosed |
| CN-115340996-A | Co-expression method of multi-subunit protein by using specific enzyme cutting site | 态创生物科技(广州)有限公司 | 2022-11-15 | — | — | CN | disclosed |
| US-20220175871-A1 | PEPTIDE HAVING ANTIOXIDANT ACTIVITY AND COMPOSITION CONTAINING SAME | SEMPIO FOODS COMPANY (KR) | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | KLK3, FOLH1, PSMA1 | DPP4 720/4885DPP8 204/4885DPP9 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.